Uso medicinal de psicodélicos e cannabis no tratamento de sintomas de transtornos mentais

##plugins.themes.bootstrap3.article.main##

Lorraine Queiroz Oliveira Pereira
Nathália Lanes Mourão
Mariana Beatriz Basso Macedo
Gustavo Bruno Martins Domingos
Kristian Cavalcanti Santos
Samantha Rodrigues Silva Cupido
Liliana Rosicler Teixeira Nunes Fava
Leticia Francine Arantes
Maria Carolina Bussade
Myrna Maria Costa de Melo Silveira

Resumo

Objetivo: Avaliar a eficácia e segurança do uso medicinal de psicodélicos e Cannabis no tratamento de sintomas de transtornos mentais, com ênfase em seu potencial como terapias alternativas em pacientes com resistência aos tratamentos convencionais. Métodos: Revisão bibliográfica integrativa no PubMed Central (PMC), através da estratégia de pesquisa: ((Cannabis) OR (Psychedelics)) AND (Psychiatric disorders) AND (Therapeutic use). Após a busca inicial, 680 estudos foram identificados, e submetidos a critérios de seleção. Após a aplicação de critérios de inclusão e exclusão, 15 artigos foram selecionados para compor este estudo. Resultados: Analisou-se o impacto da psilocibina e do MDMA no alívio dos sintomas de depressão e TEPT, bem como os efeitos do CBD e THC no manejo de ansiedade e sintomas psicóticos, além de explorar os principais riscos e efeitos adversos associados ao uso desses tratamentos, comparando-os com as terapias convencionais. Considerações finais: O uso de substâncias psicodélicas, como a psilocibina e o MDMA, apresentam resultados positivos na prática clínica, aumentando a evidência de que quando utilizados com terapias convencionais podem trazer muitos benefícios aos pacientes. Entretanto, apresenta-se como um assunto pouco protocolado atualmente. Assim, são necessárias pesquisas contínuas, a fim de padronizar as abordagens terapêuticas para garantir a minimização de efeitos adversos.

##plugins.themes.bootstrap3.article.details##

Como Citar
PereiraL. Q. O., MourãoN. L., MacedoM. B. B., DomingosG. B. M., SantosK. C., CupidoS. R. S., FavaL. R. T. N., ArantesL. F., BussadeM. C., & SilveiraM. M. C. de M. (2025). Uso medicinal de psicodélicos e cannabis no tratamento de sintomas de transtornos mentais. Revista Eletrônica Acervo Saúde, 25, e19218. https://doi.org/10.25248/reas.e19218.2025
Seção
Revisão Bibliográfica

Referências

1. AARONSON ST, et al. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Controlled Trial. JAMA Psychiatry, 2023.

2. AICHER HD, et al. Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects. Front Psychiatry, 2024; 14:1302559.

3. BINKOWSKA AA, et al. Cannabidiol usage, efficacy, and side effects: analyzing the impact of health conditions, medications, and cannabis use in a cross-sectional online pilot study. Front. Psychiatry, 2024; 15: e1356009.

4. DAMMANN I, et al. Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review. Pharmacopsychiatry, 2024."

5. DAWSON D, et al. The prevalence of cannabis use disorders in people who use medicinal cannabis: A systematic review and meta-analysis. Drug and Alcohol Dependence, 2024; 257: e111263.

6. ECKERNÄS E, et al. Optimized infusion rates for N,N-dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation framework. CPT Pharmacometrics Syst Pharmacol, 2023; 12(10):1398-1410.

7. EVANS J, et al. Extended difficulties following the use of psychedelic drugs: A mixed methods study. PLoS ONE, 2023; 18(10): e0293349."

8. HAIJEN ECHM, et al. Effects of psychedelic microdosing versus conventional ADHD medication use on emotion regulation, empathy, and ADHD symptoms in adults with severe ADHD symptoms: A naturalistic prospective comparison study. European Psychiatry, 2024; 67(1):e18.

9. KORKMAZ ND, et al.Psychedelic therapy in depression and substance use disorders. European Journal of Neuroscience, 2024."

10. MALLICK K, et al. The anxiolytic effects of cannabinoids: A comprehensive review. Pharmacology, Biochemistry and Behavior, 2024; 243: e173828.

11. MASON NL, et al. Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study. Brain Behav Immun, 2023; 114:299-310.

12. MÜLLER-VAHL KR. Cannabinoids in the treatment of selected mental illnesses: practical approach and overview of the literature. Pharmacopsychiatry, 2024; 57: 104-114

13. PEREZ N, et al. Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. European Neuropsychopharmacology 76, 2023; 61–76.

14. RAISON CL, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial. JAMA , 2023; 330 (9): 843 - 853.

15. RAJ P, et al. Psychedelic drugs of hallucinogens: exploring their medicinal potencial. Cureus, 2023; 15(11): e48719

16. SCHOUTEN M, et al. Cannabidiol and brain function: current knowledge and future perspectives. Pharmacology, 2024."

17. SLOSHOWER J, et al. Psychological fexibility as a mechanism of change in psilocybin‐assisted therapy for major depression: results from an exploratory placebo‐controlled trial. Scientific Reports, 2024.

18. SZIGETI B, et al. Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. Psychological Medicine, 2024.

19. WOJTAS A. The possible place for psychedelics in pharmacotherapy of mental disorders. Psychedelic Medicine: Therapeutic Applications and Implications for Future Research. Pharmacological Reports (2023).

20. YADEN DB, et al. IUPHAR-review: The Integration of Classic Psychedelics into Current Substance Use Disorder Treatment Models. Pharmacological Research, 2023.

21. YERUBANDI A, et al. Acute adverse effects of therapeutic doses of psilocybin: a systematic review and meta-analysis. JAMA Network Open, 2024; 7(4): e245960.